Skip to content

News & calendar

news: as of 2026-10-08
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Wed · 15 Jul

regulation

20:25
Google News: Arcosa, Inc.

Arcosa (NYSE: ACA) reports MSHA 107(a) order at New Jersey quarry

Arcosa reported that MSHA issued a 107(a) order at its New Jersey quarry.

Markets open original ↗

product

19:33
Google News: Merck & Co.

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first

Merck's Keytruda scored a front-line PD-1-first trial win in an endometrial cancer subtype.

Markets open original ↗

regulation

18:51
Google News: UnitedHealth Group

Appeals court tosses lawsuit accusing UnitedHealth of misleading seniors

An appeals court dismissed a lawsuit that had accused UnitedHealth of misleading seniors.

Markets open original ↗

regulation

18:39
Google News: Novo Nordisk

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Novo Nordisk received its first European approval for an oral Wegovy weight-loss pill.

Markets open original ↗

product

17:59
Google News: Merck & Co.

Kelun's Merck & Co.-partnered ADC scores late-stage win in front-line PD-L1-negative NSCLC

An antibody-drug conjugate Merck partnered with Kelun scored a late-stage trial win in front-line PD-L1-negative NSCLC.

Markets open original ↗

The wire

everything that arrived · 7 days